EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Arbutus Biopharma's Enterprise Value is $867.4 Mil.
Arbutus Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-34.4 Mil. Therefore, Arbutus Biopharma's EV-to-FCF for today is -25.25.
The historical rank and industry rank for Arbutus Biopharma's EV-to-FCF or its related term are showing as below:
LTS:0SGC'
s EV-to-FCF Range Over the Past 10 Years
Min: -25.25 Med: -4.63 Max: 0.29
Current: -25.25
During the past 13 years, the highest EV-to-FCF of Arbutus Biopharma was 0.29. The lowest was -25.25. And the median was -4.63.
LTS:0SGC's EV-to-FCF is ranked worse than 100% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs LTS:0SGC: -25.25
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arbutus Biopharma's PE Ratio (TTM) for today is calculated as:
Arbutus Biopharma's share price for today is $3.3188.
Arbutus Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.830.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Arbutus Biopharma EV-to-FCF Related Terms
Arbutus Biopharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0SGC vs EVMN, ANNX, TBPH: EV-to-FCF Comparison
For the Biotechnology subindustry, Arbutus Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's EV-to-FCF falls into.
Arbutus Biopharma's current Enterprise Value is $867.4 Mil.
Arbutus Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma (LTS:0SGC) has a EV-to-FCF of -25.25 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Arbutus Biopharma and its competitors. According to the industry distribution chart, Arbutus Biopharma ranks #999999 out of 332 companies in the Biotechnology industry.
Is Arbutus Biopharma's EV-to-FCF too high?
Arbutus Biopharma's current EV-to-FCF is -25.25. Based on the distribution chart, Arbutus Biopharma ranks #999999 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arbutus Biopharma has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's EV-to-FCF compare to EVMN and ANNX?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #999999 out of 332 companies for EV-to-FCF. This places Arbutus Biopharma in the lower half of its industry. The industry median EV-to-FCF is 16.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Arbutus Biopharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current EV-to-FCF is -25.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Arbutus Biopharma (LTS:0SGC) has a current EV-to-FCF of -25.25. The stock's GF Value™ is $34.87, compared to a current price of $3.32 — trading 90.5% below its estimated fair value. The current EV-to-FCF is -25.25. Arbutus Biopharma's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Arbutus Biopharma (LTS:0SGC), the current EV-to-FCF is -25.25 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (LTS:0SGC) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $3.32 is trading 90.5% below its estimated GF Value™ of $34.87.
Key valuation signals for LTS:0SGC:
EV-to-FCF: -25.25
GF Value™: $34.87 vs. price of $3.32 (90.5% below fair value)
No single metric tells the full story. See the LTS:0SGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score
Get the complete analysis for LTS:0SGC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0SGC has been successfully added to your 
